SZodixStudyAcademic Library

Shelves Open access

Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated

ChangWon C. Lee · Study

Home/Author

ChangWon C. Lee

4 works· latest 2022· 1 institutionscluster: provisionalORCID 0000-0001-7534-0526

h-index4

i104

Citations230

Works here4

18

20

21

22

Most cited in this library

Analysis of Launch and Postapproval Cancer Drug Pricing, Clinical Benefit, and Policy Implications in the US and Europe2021 · 87 citations
Medicare Spending on Brand-name Combination Medications vs Their Generic Constituents2018 · 48 citations
Market Exclusivity Length for Drugs with New Generic or Biosimilar Competition, 2012–20182020 · 48 citations
Clinical Benefit and Expedited Approval of Cancer Drugs in the United States, European Union, Switzerland, Japan, Canada, and Australia2022 · 47 citations

Works

4 shown

Clinical Benefit and Expedited Approval of Cancer Drugs in the United States, European Union, Switzerland, Japan, Canada, and Australia

JCO Oncology Practice·2022·5 authors·Open access

47citations

Analysis of Launch and Postapproval Cancer Drug Pricing, Clinical Benefit, and Policy Implications in the US and Europe

JAMA Oncology·2021·8 authors·Open access

87citations

Market Exclusivity Length for Drugs with New Generic or Biosimilar Competition, 2012–2018

Clinical Pharmacology & Therapeutics·2020·3 authors

48citations

Medicare Spending on Brand-name Combination Medications vs Their Generic Constituents

JAMA·2018·4 authors·Open access

48citations